[{"to": "283", "prefix": " by CYP2C8 and OAT3 transporters: Monitor patients because ", "from": "271", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " may increase exposure of these drugs "}, {"to": "366", "prefix": "\n                            ", "from": "354", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Teriflunomide", "suffix": " may increase exposure of ethinylestradiol and levonorgestre"}, {"to": "569", "prefix": "     Drugs metabolized by CYP1A2: Monitor patients because ", "from": "557", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " may decrease exposure of these drugs "}, {"to": "677", "prefix": "\n                            Warfarin: Monitor INR as ", "from": "665", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " may decrease INR "}, {"to": "820", "prefix": "B3 transporters: Monitor patients because ", "from": "808", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " may increase exposure of these drugs "}, {"to": "1331", "prefix": "ubstrates\n                        \n                        ", "from": "1319", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Teriflunomide", "suffix": " is an inhibitor of CYP2C8 in vivo.  In patients taking AUBA"}, {"to": "3014", "prefix": "ubstrates\n                        \n                        ", "from": "3002", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Teriflunomide", "suffix": " may be a weak inducer of CYP1A2 in vivo. In patients taking"}, {"to": "3698", "prefix": "bstrates \n                        \n                        ", "from": "3686", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Teriflunomide", "suffix": " inhibits the activity of OAT3 in vivo. In patients taking A"}, {"to": "4478", "prefix": "ubstrates\n                        \n                        ", "from": "4466", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Teriflunomide", "suffix": " inhibits the activity of BCRP and OATP1B1"}, {"to": "427", "prefix": "eriflunomide may increase exposure of ethinylestradiol and ", "from": "414", "name": "Levonorgestrel", "fullId": "http://purl.bioontology.org/ontology/MESH/D016912", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "levonorgestrel", "suffix": ". Choose an appropriate oral contraceptive "}, {"to": "2542", "prefix": "ay increase the systemic exposures of ethinylestradiol and ", "from": "2529", "name": "Levonorgestrel", "fullId": "http://purl.bioontology.org/ontology/MESH/D016912", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "levonorgestrel", "suffix": ". Consideration should be given to the type or dose of contr"}, {"to": "647", "prefix": "\n                            ", "from": "640", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Warfarin", "suffix": ": Monitor INR as teriflunomide may decrease INR "}, {"to": "1916", "prefix": "          \n                           Effect of AUBAGIO on ", "from": "1909", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "warfarin", "suffix": "\n                        \n                        Coadminist"}, {"to": "2007", "prefix": " \n                        Coadministration of AUBAGIO with ", "from": "2000", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "warfarin", "suffix": " requires close monitoring of the international normalized r"}, {"to": "902", "prefix": "\n                            ", "from": "891", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Rosuvastatin", "suffix": ": The dose of rosuvastatin should not exceed 10 mg once dail"}, {"to": "928", "prefix": "\n                            Rosuvastatin: The dose of ", "from": "917", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "rosuvastatin", "suffix": " should not exceed 10 mg once daily in patients taking AUBAG"}, {"to": "4588", "prefix": "1B3 in vivo. For a patient taking AUBAGIO, the dose of ", "from": "4577", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "rosuvastatin", "suffix": " should not exceed 10 mg once daily. For other substrates of"}, {"to": "990", "prefix": "atin should not exceed 10 mg once daily in patients taking ", "from": "984", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " "}, {"to": "1247", "prefix": "                     \n                           Effect of ", "from": "1241", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " on CYP2C8 substrates\n                        \n             "}, {"to": "1394", "prefix": "ide is an inhibitor of CYP2C8 in vivo.  In patients taking ", "from": "1388", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": ", exposure of drugs metabolized by CYP2C8 "}, {"to": "1904", "prefix": "                     \n                           Effect of ", "from": "1898", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " on warfarin\n                        \n                      "}, {"to": "1993", "prefix": "              \n                        Coadministration of ", "from": "1987", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " with warfarin requires close monitoring of the internationa"}, {"to": "2093", "prefix": " because ", "from": "2087", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " may decrease peak INR by approximately 25%.\n               "}, {"to": "2387", "prefix": "                     \n                           Effect of ", "from": "2381", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " on oral contraceptives\n                        \n           "}, {"to": "2467", "prefix": "aceptives\n                        \n                        ", "from": "2461", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " may increase the systemic exposures of ethinylestradiol and"}, {"to": "2644", "prefix": "he type or dose of contraceptives used in combination with ", "from": "2638", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " [see Clinical Pharmacology "}, {"to": "2930", "prefix": "                     \n                           Effect of ", "from": "2924", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " on CYP1A2 substrates\n                        \n             "}, {"to": "3082", "prefix": "ay be a weak inducer of CYP1A2 in vivo. In patients taking ", "from": "3076", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": ", exposure of drugs metabolized by CYP1A2 "}, {"to": "3585", "prefix": "                     \n                           Effect of ", "from": "3579", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " on organic anion transporter 3 "}, {"to": "3764", "prefix": " inhibits the activity of OAT3 in vivo. In patients taking ", "from": "3758", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": ", exposure of drugs which are OAT3 substrates "}, {"to": "4329", "prefix": "                     \n                           Effect of ", "from": "4323", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " on BCRP and organic anion transporting polypeptide B1 and B"}, {"to": "4562", "prefix": "1B3 in vivo. For a patient taking ", "from": "4556", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": ", the dose of rosuvastatin should not exceed 10 mg once dail"}, {"to": "5016", "prefix": "increased exposures to the drugs while patients are taking ", "from": "5010", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " [see Clinical Pharmacology "}, {"to": "1453", "prefix": "e.g., ", "from": "1444", "name": "Paclitaxel", "fullId": "http://purl.bioontology.org/ontology/MESH/D017239", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "paclitaxel", "suffix": ", pioglitazone, repaglinide, rosiglitazone"}, {"to": "1467", "prefix": "e.g., paclitaxel, ", "from": "1456", "name": "pioglitazone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/33738", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "pioglitazone", "suffix": ", repaglinide, rosiglitazone"}, {"to": "1480", "prefix": "e.g., paclitaxel, pioglitazone, ", "from": "1470", "name": "repaglinide", "fullId": "http://purl.bioontology.org/ontology/MESH/C072379", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "repaglinide", "suffix": ", rosiglitazone"}, {"to": "4833", "prefix": "e.g., atorvastatin, nateglinide, pravastatin, ", "from": "4823", "name": "repaglinide", "fullId": "http://purl.bioontology.org/ontology/MESH/C072379", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "repaglinide", "suffix": ", and simvastatin"}, {"to": "1495", "prefix": "e.g., paclitaxel, pioglitazone, repaglinide, ", "from": "1483", "name": "rosiglitazone", "fullId": "http://purl.bioontology.org/ontology/MESH/C089730", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "rosiglitazone", "suffix": ""}, {"to": "3140", "prefix": "e.g., ", "from": "3132", "name": "alosetron", "fullId": "http://purl.bioontology.org/ontology/MESH/C090840", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "alosetron", "suffix": ", duloxetine, theophylline, tizanidine"}, {"to": "3152", "prefix": "e.g., alosetron, ", "from": "3143", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "duloxetine", "suffix": ", theophylline, tizanidine"}, {"to": "3166", "prefix": "e.g., alosetron, duloxetine, ", "from": "3155", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "theophylline", "suffix": ", tizanidine"}, {"to": "3178", "prefix": "e.g., alosetron, duloxetine, theophylline, ", "from": "3169", "name": "tizanidine", "fullId": "http://purl.bioontology.org/ontology/MESH/C023754", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "tizanidine", "suffix": ""}, {"to": "3825", "prefix": "e.g., ", "from": "3818", "name": "Cefaclor", "fullId": "http://purl.bioontology.org/ontology/MESH/D002433", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "cefaclor", "suffix": ", cimetidine, ciprofloxacin, penicillin G, ketoprofen, furos"}, {"to": "3837", "prefix": "e.g., cefaclor, ", "from": "3828", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "cimetidine", "suffix": ", ciprofloxacin, penicillin G, ketoprofen, furosemide, metho"}, {"to": "3852", "prefix": "e.g., cefaclor, cimetidine, ", "from": "3840", "name": "Ciprofloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2551", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "ciprofloxacin", "suffix": ", penicillin G, ketoprofen, furosemide, methotrexate, zidovu"}, {"to": "3866", "prefix": "e.g., cefaclor, cimetidine, ciprofloxacin, ", "from": "3855", "name": "Penicillin G", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7980", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "penicillin G", "suffix": ", ketoprofen, furosemide, methotrexate, zidovudine"}, {"to": "3878", "prefix": "e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ", "from": "3869", "name": "Ketoprofen", "fullId": "http://purl.bioontology.org/ontology/MESH/D007660", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "ketoprofen", "suffix": ", furosemide, methotrexate, zidovudine"}, {"to": "3890", "prefix": "clor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, ", "from": "3881", "name": "Furosemide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4603", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "furosemide", "suffix": ", methotrexate, zidovudine"}, {"to": "3904", "prefix": "dine, ciprofloxacin, penicillin G, ketoprofen, furosemide, ", "from": "3893", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "methotrexate", "suffix": ", zidovudine"}, {"to": "4723", "prefix": "e.g., ", "from": "4712", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "methotrexate", "suffix": ", rifampin"}, {"to": "3916", "prefix": "xacin, penicillin G, ketoprofen, furosemide, methotrexate, ", "from": "3907", "name": "Zidovudine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11413", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "zidovudine", "suffix": ""}, {"to": "4673", "prefix": "e.g., ", "from": "4662", "name": "Mitoxantrone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7005", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "mitoxantrone", "suffix": ""}, {"to": "4733", "prefix": "e.g., methotrexate, ", "from": "4726", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "rifampin", "suffix": ""}, {"to": "4794", "prefix": "e.g., ", "from": "4783", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "atorvastatin", "suffix": ", nateglinide, pravastatin, repaglinide, and simvastatin"}, {"to": "4807", "prefix": "e.g., atorvastatin, ", "from": "4797", "name": "nateglinide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/274332", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "nateglinide", "suffix": ", pravastatin, repaglinide, and simvastatin"}, {"to": "4820", "prefix": "e.g., atorvastatin, nateglinide, ", "from": "4810", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "pravastatin", "suffix": ", repaglinide, and simvastatin"}, {"to": "4850", "prefix": ", atorvastatin, nateglinide, pravastatin, repaglinide, and ", "from": "4840", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "simvastatin", "suffix": ""}, {"to": "292", "prefix": "\n                     \n                        ", "from": "283", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " is metabolized by sphingosine kinase to the active metaboli"}, {"to": "366", "prefix": "etabolized by sphingosine kinase to the active metabolite, ", "from": "357", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphat"}, {"to": "388", "prefix": "ine kinase to the active metabolite, fingolimod-phosphate. ", "from": "379", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": "-phosphate is a sphingosine 1-phosphate receptor modulator, "}, {"to": "540", "prefix": "inity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. ", "from": "531", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": "-phosphate blocks the capacity of lymphocytes to egress from"}, {"to": "703", "prefix": "of lymphocytes in peripheral blood. The mechanism by which ", "from": "694", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " exerts therapeutic effects in multiple sclerosis is unknown"}, {"to": "1216", "prefix": "nd Rhythm\n                        \n                        ", "from": "1207", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " causes a transient reduction in heart rate and AV conductio"}, {"to": "1656", "prefix": "f heart rate and response to exercise, are not affected by ", "from": "1647", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " treatment. \n                        Fingolimod treatment is"}, {"to": "1703", "prefix": "affected by fingolimod treatment. \n                        ", "from": "1694", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " treatment is not associated with a decrease in cardiac outp"}, {"to": "1974", "prefix": "In a thorough QT interval study of doses of 1.25 or 2.5 mg ", "from": "1965", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " at steady-state, when a negative chronotropic effect of fin"}, {"to": "2041", "prefix": "od at steady-state, when a negative chronotropic effect of ", "from": "2032", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " was still present, fingolimod treatment resulted in a prolo"}, {"to": "2071", "prefix": "ative chronotropic effect of fingolimod was still present, ", "from": "2062", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " treatment resulted in a prolongation of QTc, with the upper"}, {"to": "2328", "prefix": ", either absolute or change from baseline, associated with ", "from": "2319", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " treatment. In MS studies, there was no clinically relevant "}, {"to": "3170", "prefix": "of whom 425 received ", "from": "3161", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " 0.5 mg daily and 418 received placebo"}, {"to": "3247", "prefix": " of patients on ", "from": "3238", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " 0.5 mg reached a nadir of "}, {"to": "3501", "prefix": " of GILENYA 0.5 mg daily. \n                        Chronic ", "from": "3492", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " dosing leads to a mild decrease in the neutrophil count to "}, {"to": "3630", "prefix": "approximately 80% of baseline. Monocytes are unaffected by ", "from": "3621", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": ".\n                        Peripheral lymphocyte count increa"}, {"to": "3740", "prefix": "hocyte count increases are evident within days of stopping ", "from": "3731", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " treatment and typically normal counts are reached within 1 "}, {"to": "5158", "prefix": "placebo. Immunologic responses were further decreased with ", "from": "5149", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " 1.25 mg "}, {"to": "6067", "prefix": "on\n                        \n                        Single ", "from": "6058", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " doses "}, {"to": "6234", "prefix": "day, ", "from": "6225", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "  was not associated with impaired oxygenation or oxygen desa"}, {"to": "6396", "prefix": "ease in airway responsiveness to methacholine.  Subjects on ", "from": "6387", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " treatment had a normal bronchodilator response to inhaled b"}, {"to": "6727", "prefix": "at 6 hours after dosing was observed in patients receiving ", "from": "6718", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " 1.25 mg "}, {"to": "6817", "prefix": " on Day 10 of treatment. ", "from": "6808", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " 1.25 mg was associated with a 5-fold increase in the use of"}, {"to": "7282", "prefix": "                      \n                        The Tmax  of ", "from": "7273", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " is 12-16 hours. The apparent absolute oral bioavailability  "}, {"to": "7437", "prefix": " of ", "from": "7428", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " or fingolimod-phosphate. Therefore GILENYA may be taken wit"}, {"to": "7451", "prefix": " of fingolimod or ", "from": "7442", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate. Therefore GILENYA may be taken without regard to"}, {"to": "7856", "prefix": "tribution\n                        \n                        ", "from": "7847", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " highly "}, {"to": "7912", "prefix": " distributes in red blood cells. ", "from": "7903", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": "-phosphate has a smaller uptake in blood cells of "}, {"to": "7978", "prefix": "17%. ", "from": "7969", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " and fingolimod-phosphate are "}, {"to": "7993", "prefix": "17%. Fingolimod and ", "from": "7984", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate are "}, {"to": "8040", "prefix": "99.7% protein bound. ", "from": "8031", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " and fingolimod-phosphate protein binding is not altered by "}, {"to": "8055", "prefix": "99.7% protein bound. Fingolimod and ", "from": "8046", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate protein binding is not altered by renal or hepati"}, {"to": "8164", "prefix": "d by renal or hepatic impairment. \n                        ", "from": "8155", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " is extensively distributed to body tissues  with a volume of"}, {"to": "8407", "prefix": "         \n                        The biotransformation of ", "from": "8398", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " in humans occurs by 3 main pathways: by reversible stereose"}, {"to": "8551", "prefix": "-enantiomer of ", "from": "8542", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate, by oxidative biotransformation catalyzed mainly "}, {"to": "8839", "prefix": "f pharmacologically inactive non-polar ceramide analogs of ", "from": "8830", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": ".\n                        Inhibitors or inducers of CYP4F2 a"}, {"to": "8970", "prefix": " possibly other CYP4F isozymes might alter the exposure of ", "from": "8961", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " or fingolimod-phosphate. In vitro studies in hepatocytes in"}, {"to": "8984", "prefix": "r CYP4F isozymes might alter the exposure of fingolimod or ", "from": "8975", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate. In vitro studies in hepatocytes indicated that C"}, {"to": "9078", "prefix": "ies in hepatocytes indicated that CYP3A4 may contribute to ", "from": "9069", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " metabolism in the case of strong induction of CYP3A4.\n     "}, {"to": "9213", "prefix": "             Following single oral administration of [14C] ", "from": "9204", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": ", the major fingolimod-related components in blood, as judge"}, {"to": "9235", "prefix": " single oral administration of [14C] fingolimod, the major ", "from": "9226", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-related components in blood, as judged from their contribut"}, {"to": "9384", "prefix": " 816 hours post-dose of total radiolabeled components, are ", "from": "9375", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " itself "}, {"to": "9411", "prefix": ", ", "from": "9402", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate "}, {"to": "9688", "prefix": "imination\n                        \n                        ", "from": "9679", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " blood clearance is 6.3 "}, {"to": "9814", "prefix": " is 6 to 9 days. Blood levels of ", "from": "9805", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate decline in parallel with those of fingolimod in t"}, {"to": "9869", "prefix": " of fingolimod-phosphate decline in parallel with those of ", "from": "9860", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " in the terminal phase, yielding similar half-lives for both"}, {"to": "10071", "prefix": "e is slowly excreted in the urine as inactive metabolites. ", "from": "10062", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " and fingolimod-phosphate are not excreted intact in urine b"}, {"to": "10086", "prefix": "reted in the urine as inactive metabolites. Fingolimod and ", "from": "10077", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate are not excreted intact in urine but are the majo"}, {"to": "10842", "prefix": "         Gender has no clinically significant influence on ", "from": "10833", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " and fingolimod-phosphate pharmacokinetics.\n                "}, {"to": "10857", "prefix": " has no clinically significant influence on fingolimod and ", "from": "10848", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate pharmacokinetics.\n                        \n      "}, {"to": "11025", "prefix": "           \n                        The effects of race on ", "from": "11016", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " and fingolimod-phosphate pharmacokinetics cannot be adequat"}, {"to": "11040", "prefix": "                     The effects of race on fingolimod and ", "from": "11031", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate pharmacokinetics cannot be adequately assessed du"}, {"to": "11335", "prefix": "                 In patients with severe renal impairment, ", "from": "11326", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " Cmax and AUC are increased by 32% and 43%, respectively, an"}, {"to": "11407", "prefix": "ax and AUC are increased by 32% and 43%, respectively, and ", "from": "11398", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate Cmax and AUC are increased by 25% and 14%, respec"}, {"to": "12143", "prefix": ", no change in ", "from": "12134", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " Cmax was observed, but fingolimod AUC0-"}, {"to": "12177", "prefix": ", no change in fingolimod Cmax was observed, but ", "from": "12168", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " AUC0-"}, {"to": "12310", "prefix": ", ", "from": "12301", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate Cmax was decreased by 22% and AUC0-96 hours was d"}, {"to": "12421", "prefix": "UC0-96 hours was decreased by 29%. The pharmacokinetics of ", "from": "12412", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate was not evaluated in patients with mild or modera"}, {"to": "12552", "prefix": " hepatic impairment. The apparent elimination half-life of ", "from": "12543", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " is unchanged in subjects with mild hepatic impairment, but "}, {"to": "13378", "prefix": " 200 mg twice-daily at steady-state and a single dose of ", "from": "13369", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " 5 mg led to a 70% increase in AUC of fingolimod and fingoli"}, {"to": "13426", "prefix": "le dose of fingolimod 5 mg led to a 70% increase in AUC of ", "from": "13417", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " and fingolimod-phosphate. Patients who use GILENYA and syst"}, {"to": "13441", "prefix": "olimod 5 mg led to a 70% increase in AUC of fingolimod and ", "from": "13432", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate. Patients who use GILENYA and systemic ketoconazo"}, {"to": "13872", "prefix": " 600 mg twice-daily at steady-state and a single dose of ", "from": "13863", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " 2 mg decreased blood concentrations "}, {"to": "13928", "prefix": " of ", "from": "13919", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " and fingolimod-phosphate by approximately 40%. The clinical"}, {"to": "13943", "prefix": " of fingolimod and ", "from": "13934", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate by approximately 40%. The clinical impact of this"}, {"to": "14184", "prefix": "s wort, may also reduce AUC of ", "from": "14175", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " and fingolimod-phosphate. The clinical impact of this poten"}, {"to": "14199", "prefix": "s wort, may also reduce AUC of fingolimod and ", "from": "14190", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate. The clinical impact of this potential decrease i"}, {"to": "14345", "prefix": "                  \n                           Potential of ", "from": "14336", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " and Fingolimod-phosphate to Inhibit the Metabolism of Comed"}, {"to": "14360", "prefix": "   \n                           Potential of Fingolimod and ", "from": "14351", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": "-phosphate to Inhibit the Metabolism of Comedications\n      "}, {"to": "14594", "prefix": "s and specific metabolic probe substrates demonstrate that ", "from": "14585", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " has little or no capacity to inhibit the activity of the fo"}, {"to": "14774", "prefix": "", "from": "14765", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " only"}, {"to": "14806", "prefix": ", and similarly ", "from": "14797", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate has little or no capacity to inhibit the activity"}, {"to": "15043", "prefix": "ers of magnitude of therapeutic concentrations. Therefore, ", "from": "15034", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " and fingolimod-phosphate are unlikely to reduce the clearan"}, {"to": "15058", "prefix": "e of therapeutic concentrations. Therefore, fingolimod and ", "from": "15049", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate are unlikely to reduce the clearance of drugs tha"}, {"to": "15288", "prefix": "                  \n                           Potential of ", "from": "15279", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " and Fingolimod-phosphate to Induce its Own and"}, {"to": "15303", "prefix": "   \n                           Potential of Fingolimod and ", "from": "15294", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": "-phosphate to Induce its Own and"}, {"to": "15430", "prefix": "dications\n                        \n                        ", "from": "15421", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " was examined for its potential to induce human CYP3A4, CYP1"}, {"to": "15645", "prefix": "CYP2C19, and CYP4F2 activity in primary human hepatocytes. ", "from": "15636", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " did not induce mRNA or activity of the different CYP enzyme"}, {"to": "15844", "prefix": "ly relevant induction of the tested CYP enzymes or MDR1 by ", "from": "15835", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " are expected at therapeutic concentrations. Fingolimod-phos"}, {"to": "15899", "prefix": " by fingolimod are expected at therapeutic concentrations. ", "from": "15890", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": "-phosphate was also examined for its potential to induce mRN"}, {"to": "16074", "prefix": "2C8, CYP2C9, CYP2C19, CYP3A, CYP4F2, CYP4F3B, and CYP4F12. ", "from": "16065", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": "-phosphate is not expected to have clinically significant in"}, {"to": "16200", "prefix": " induction effects on these enzymes at therapeutic dose of ", "from": "16191", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": ". In vitro experiments did not provide an indication of CYP "}, {"to": "16283", "prefix": "eriments did not provide an indication of CYP induction by ", "from": "16274", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate.\n                        \n                       "}, {"to": "16444", "prefix": "          \n                        Based on in vitro data, ", "from": "16435", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " as well as fingolimod-phosphate are not expected to inhibit"}, {"to": "16466", "prefix": "             Based on in vitro data, fingolimod as well as ", "from": "16457", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate are not expected to inhibit the uptake of comedic"}, {"to": "17138", "prefix": "          \n                        The coadministration of ", "from": "17129", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " 0.5 mg daily with oral contraceptives "}, {"to": "17307", "prefix": "ically significant change in oral contraceptives exposure. ", "from": "17298", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Fingolimod", "suffix": " and fingolimod-phosphate exposure were consistent with thos"}, {"to": "17322", "prefix": "ant change in oral contraceptives exposure. Fingolimod and ", "from": "17313", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate exposure were consistent with those from previous"}, {"to": "17523", "prefix": "tives containing other progestagens; however, an effect of ", "from": "17514", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " on their exposure is not expected.\n                        "}, {"to": "17719", "prefix": "                       The pharmacokinetics of single-dose ", "from": "17710", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " was not altered during coadministration with cyclosporine a"}, {"to": "17867", "prefix": " was cyclosporine steady-state pharmacokinetics altered by ", "from": "17858", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": ". These data indicate that GILENYA is unlikely to reduce or "}, {"to": "18080", "prefix": ", MRP2, and OATP-1B1 does not influence ", "from": "18071", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " disposition. \n                        \n                    "}, {"to": "18267", "prefix": "                      \n                        Single-dose ", "from": "18258", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " and fingolimod-phosphate exposure was not altered by coadmi"}, {"to": "18282", "prefix": "       \n                        Single-dose fingolimod and ", "from": "18273", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate exposure was not altered by coadministered isopro"}, {"to": "18419", "prefix": "or atropine. Likewise, the single-dose pharmacokinetics of ", "from": "18410", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " and fingolimod-phosphate and the steady-state pharmacokinet"}, {"to": "18434", "prefix": "kewise, the single-dose pharmacokinetics of fingolimod and ", "from": "18425", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate and the steady-state pharmacokinetics of both ate"}, {"to": "18607", "prefix": "e coadministration of the latter 2 drugs individually with ", "from": "18598", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": ". \n                        \n                           Popul"}, {"to": "18933", "prefix": " on ", "from": "18924", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " or fingolimod-phosphate predose concentrations. In addition"}, {"to": "18947", "prefix": " on fingolimod or ", "from": "18938", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate predose concentrations. In addition, the followin"}, {"to": "19096", "prefix": " on ", "from": "19087", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " or fingolimod-phosphate predose concentrations: baclofen, g"}, {"to": "19110", "prefix": " on fingolimod or ", "from": "19101", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1012892", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate predose concentrations: baclofen, gabapentin, oxy"}, {"to": "2785", "prefix": "                  In a study in which 12 subjects received ", "from": "2779", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " 0.5 mg daily, the lymphocyte count decreased to approximate"}, {"to": "3443", "prefix": "phocyte counts are maintained with chronic daily dosing of ", "from": "3437", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " 0.5 mg daily. \n                        Chronic fingolimod d"}, {"to": "3949", "prefix": " Response\n                        \n                        ", "from": "3943", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " reduces the immune response to vaccination, as evaluated in"}, {"to": "4443", "prefix": "n response to KLH and PPV-23, respectively, in subjects on ", "from": "4437", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " 0.5 mg. Similarly, IgG titers were decreased by 45% and 50%"}, {"to": "4572", "prefix": "n response to KLH and PPV-23, respectively, in subjects on ", "from": "4566", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " 0.5 mg daily compared to placebo. The responder rate for GI"}, {"to": "4637", "prefix": "A 0.5 mg daily compared to placebo. The responder rate for ", "from": "4631", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " 0.5 mg as measured by the number of subjects with a "}, {"to": "5062", "prefix": "s toxoid was decreased by approximately 30% in subjects on ", "from": "5056", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " 0.5 mg daily, compared to placebo. Immunologic responses we"}, {"to": "5468", "prefix": "week steady-state, randomized, placebo-controlled study of ", "from": "5462", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " 0.5 mg in multiple sclerosis patients "}, {"to": "5697", "prefix": "against at least 1 of the 3 influenza strains, was 54% for ", "from": "5691", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " 0.5 mg and 85% in the placebo group. The responder rate 3 w"}, {"to": "5892", "prefix": "se in antibody directed against tetanus toxoid was 40% for ", "from": "5886", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " 0.5 mg and 61% in the placebo group.\n                      "}, {"to": "6595", "prefix": "y of patients with moderate asthma, no effect was seen for ", "from": "6589", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " 0.5 mg "}, {"to": "7480", "prefix": " of fingolimod or fingolimod-phosphate. Therefore ", "from": "7474", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " may be taken without regard to meals.\n                     "}, {"to": "11561", "prefix": "parent elimination half-life. Based on these findings, the ", "from": "11555", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " 0.5 mg dose is appropriate for use in patients with renal i"}, {"to": "13477", "prefix": "C of fingolimod and fingolimod-phosphate. Patients who use ", "from": "13471", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " and systemic ketoconazole concomitantly should be closely m"}, {"to": "17901", "prefix": "cokinetics altered by fingolimod. These data indicate that ", "from": "17895", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " is unlikely to reduce or increase the clearance of drugs cl"}, {"to": "322", "prefix": "     \n                        Fingolimod is metabolized by ", "from": "312", "name": "Sphingosine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013110", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "sphingosine", "suffix": " kinase to the active metabolite, fingolimod-phosphate. Fing"}, {"to": "4210", "prefix": " immunization were assessed by IgM and ", "from": "4208", "name": "Immunoglobulin G", "fullId": "http://purl.bioontology.org/ontology/MESH/D007074", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "IgG", "suffix": " titers in a steady-state, randomized, placebo-controlled st"}, {"to": "4466", "prefix": "3, respectively, in subjects on GILENYA 0.5 mg. Similarly, ", "from": "4464", "name": "Immunoglobulin G", "fullId": "http://purl.bioontology.org/ontology/MESH/D007074", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "IgG", "suffix": " titers were decreased by 45% and 50%, in response to KLH an"}, {"to": "4717", "prefix": "4-fold increase in KLH ", "from": "4715", "name": "Immunoglobulin G", "fullId": "http://purl.bioontology.org/ontology/MESH/D007074", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "IgG", "suffix": " was comparable to placebo and 25% lower for PPV-23 IgG, whi"}, {"to": "4772", "prefix": "KLH IgG was comparable to placebo and 25% lower for PPV-23 ", "from": "4770", "name": "Immunoglobulin G", "fullId": "http://purl.bioontology.org/ontology/MESH/D007074", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "IgG", "suffix": ", while the number of subjects with a "}, {"to": "5004", "prefix": "skin delayed-type hypersensitivity reaction to Candida and ", "from": "4991", "name": "Tetanus Toxoid", "fullId": "http://purl.bioontology.org/ontology/MESH/D013745", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "tetanus toxoid", "suffix": " was decreased by approximately 30% in subjects on GILENYA 0"}, {"to": "5368", "prefix": "munogenicity of Northern hemisphere seasonal influenza and ", "from": "5355", "name": "Tetanus Toxoid", "fullId": "http://purl.bioontology.org/ontology/MESH/D013745", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "tetanus toxoid", "suffix": " vaccination was assessed in a 12-week steady-state, randomi"}, {"to": "5872", "prefix": "4-fold increase in antibody directed against ", "from": "5859", "name": "Tetanus Toxoid", "fullId": "http://purl.bioontology.org/ontology/MESH/D013745", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "tetanus toxoid", "suffix": " was 40% for GILENYA 0.5 mg and 61% in the placebo group.\n  "}, {"to": "6372", "prefix": "n with exercise or an increase in airway responsiveness to ", "from": "6361", "name": "Methacholine Chloride", "fullId": "http://purl.bioontology.org/ontology/MESH/D016210", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "methacholine", "suffix": ".  Subjects on fingolimod treatment had a normal bronchodilat"}, {"to": "13185", "prefix": "      \n                        \n                           ", "from": "13174", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D007654", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Ketoconazole", "suffix": "\n                        \n                        The coadmi"}, {"to": "13271", "prefix": "          \n                        The coadministration of ", "from": "13260", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D007654", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "ketoconazole", "suffix": " "}, {"to": "13503", "prefix": "ingolimod-phosphate. Patients who use GILENYA and systemic ", "from": "13492", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D007654", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "ketoconazole", "suffix": " concomitantly should be closely monitored, as the risk of a"}, {"to": "13685", "prefix": "].\n                        \n                           ", "from": "13673", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Carbamazepine", "suffix": "\n                        \n                        The coadmi"}, {"to": "13772", "prefix": "          \n                        The coadministration of ", "from": "13760", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "carbamazepine", "suffix": " "}, {"to": "14102", "prefix": "                Other strong CYP450 enzyme inducers, e.g., ", "from": "14093", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "rifampicin", "suffix": ", phenytoin, phenobarbital, and St. John"}, {"to": "14113", "prefix": "    Other strong CYP450 enzyme inducers, e.g., rifampicin, ", "from": "14105", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "phenytoin", "suffix": ", phenobarbital, and St. John"}, {"to": "14128", "prefix": "trong CYP450 enzyme inducers, e.g., rifampicin, phenytoin, ", "from": "14116", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "phenobarbital", "suffix": ", and St. John"}, {"to": "17213", "prefix": "ethinylestradiol and ", "from": "17200", "name": "Levonorgestrel", "fullId": "http://purl.bioontology.org/ontology/MESH/D016912", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "levonorgestrel", "suffix": ""}, {"to": "17623", "prefix": "ected.\n                        \n                           ", "from": "17612", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Cyclosporine", "suffix": "\n                        \n                        The pharma"}, {"to": "17777", "prefix": "se fingolimod was not altered during coadministration with ", "from": "17766", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "cyclosporine", "suffix": " at steady-state, nor was cyclosporine steady-state pharmaco"}, {"to": "17815", "prefix": "oadministration with cyclosporine at steady-state, nor was ", "from": "17804", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "cyclosporine", "suffix": " steady-state pharmacokinetics altered by fingolimod. These "}, {"to": "18160", "prefix": "tion. \n                        \n                           ", "from": "18148", "name": "Isoproterenol", "fullId": "http://purl.bioontology.org/ontology/MESH/D007545", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Isoproterenol", "suffix": ", Atropine, Atenolol, and Diltiazem\n                        "}, {"to": "18349", "prefix": "limod-phosphate exposure was not altered by coadministered ", "from": "18337", "name": "Isoproterenol", "fullId": "http://purl.bioontology.org/ontology/MESH/D007545", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "isoproterenol", "suffix": " or atropine. Likewise, the single-dose pharmacokinetics of "}, {"to": "18170", "prefix": "                \n                           Isoproterenol, ", "from": "18163", "name": "Atropine", "fullId": "http://purl.bioontology.org/ontology/MESH/D001285", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Atropine", "suffix": ", Atenolol, and Diltiazem\n                        \n         "}, {"to": "18361", "prefix": "xposure was not altered by coadministered isoproterenol or ", "from": "18354", "name": "Atropine", "fullId": "http://purl.bioontology.org/ontology/MESH/D001285", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "atropine", "suffix": ". Likewise, the single-dose pharmacokinetics of fingolimod a"}, {"to": "18180", "prefix": "      \n                           Isoproterenol, Atropine, ", "from": "18173", "name": "Atenolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1202", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Atenolol", "suffix": ", and Diltiazem\n                        \n                   "}, {"to": "18499", "prefix": "od-phosphate and the steady-state pharmacokinetics of both ", "from": "18492", "name": "Atenolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1202", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "atenolol", "suffix": " and diltiazem were unchanged during the coadministration of"}, {"to": "18195", "prefix": "                    Isoproterenol, Atropine, Atenolol, and ", "from": "18187", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Diltiazem", "suffix": "\n                        \n                        Single-dos"}, {"to": "18513", "prefix": "and the steady-state pharmacokinetics of both atenolol and ", "from": "18505", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "diltiazem", "suffix": " were unchanged during the coadministration of the latter 2 "}, {"to": "18877", "prefix": "ients did not provide evidence for a significant effect of ", "from": "18868", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fluoxetine", "suffix": " and paroxetine "}, {"to": "18892", "prefix": "rovide evidence for a significant effect of fluoxetine and ", "from": "18883", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "paroxetine", "suffix": " "}, {"to": "19153", "prefix": "fingolimod or fingolimod-phosphate predose concentrations: ", "from": "19146", "name": "Baclofen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1292", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "baclofen", "suffix": ", gabapentin, oxybutynin, amantadine, modafinil, amitriptyli"}, {"to": "19165", "prefix": " or fingolimod-phosphate predose concentrations: baclofen, ", "from": "19156", "name": "gabapentin", "fullId": "http://purl.bioontology.org/ontology/MESH/C040029", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "gabapentin", "suffix": ", oxybutynin, amantadine, modafinil, amitriptyline, pregabal"}, {"to": "19177", "prefix": "od-phosphate predose concentrations: baclofen, gabapentin, ", "from": "19168", "name": "oxybutynin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32675", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "oxybutynin", "suffix": ", amantadine, modafinil, amitriptyline, pregabalin, and cort"}, {"to": "19189", "prefix": " predose concentrations: baclofen, gabapentin, oxybutynin, ", "from": "19180", "name": "Amantadine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/620", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "amantadine", "suffix": ", modafinil, amitriptyline, pregabalin, and corticosteroids."}, {"to": "19200", "prefix": "centrations: baclofen, gabapentin, oxybutynin, amantadine, ", "from": "19192", "name": "modafinil", "fullId": "http://purl.bioontology.org/ontology/MESH/C048833", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "modafinil", "suffix": ", amitriptyline, pregabalin, and corticosteroids. \n         "}, {"to": "19215", "prefix": ": baclofen, gabapentin, oxybutynin, amantadine, modafinil, ", "from": "19203", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "amitriptyline", "suffix": ", pregabalin, and corticosteroids. \n                     \n  "}, {"to": "19227", "prefix": "apentin, oxybutynin, amantadine, modafinil, amitriptyline, ", "from": "19218", "name": "pregabalin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/187832", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "pregabalin", "suffix": ", and corticosteroids. \n                     \n              "}, {"to": "199", "prefix": " QT Prolonging Drugs \n                  \n                  ", "from": "193", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " has not been studied in patients treated with drugs that pr"}, {"to": "429", "prefix": " pointes in patients with bradycardia. Since initiation of ", "from": "423", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " treatment results in decreased heart rate and may prolong t"}, {"to": "915", "prefix": "e\n                  \n                  The blood levels of ", "from": "906", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": " and fingolimod-phosphate are increased by 1.7-fold when use"}, {"to": "930", "prefix": "     \n                  The blood levels of fingolimod and ", "from": "921", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "fingolimod", "suffix": "-phosphate are increased by 1.7-fold when used concomitantly"}, {"to": "1034", "prefix": "hen used concomitantly with ketoconazole. Patients who use ", "from": "1028", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " and systemic ketoconazole concomitantly should be closely m"}, {"to": "1242", "prefix": "             Vaccines\n                  \n                  ", "from": "1236", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " reduces the immune response to vaccination. Vaccination may"}, {"to": "1398", "prefix": "for up to 2 months after discontinuation of treatment with ", "from": "1392", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " [see Clinical Pharmacology "}, {"to": "1529", "prefix": "ated vaccines during and for 2 months after treatment with ", "from": "1523", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " because of the risk of infection.\n"}, {"to": "1981", "prefix": "t be considered if these therapies are coadministered with ", "from": "1975", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": ". When switching from drugs with prolonged immune effects, s"}, {"to": "2236", "prefix": "ntended additive immunosuppressive effects when initiating ", "from": "2230", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " [see Warnings and Precautions "}, {"to": "2468", "prefix": "\n                  \n                  Experience with ", "from": "2462", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " in patients receiving concurrent therapy with drugs that sl"}, {"to": "2728", "prefix": " is limited. Because initiation of ", "from": "2722", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " treatment may result in an additional decrease in heart rat"}, {"to": "2836", "prefix": "rease in heart rate, concomitant use of these drugs during ", "from": "2830", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " initiation may be associated with severe bradycardia or hea"}, {"to": "3082", "prefix": "eart rate or atrioventricular conduction before initiating ", "from": "3076", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": ". Patients who cannot switch, should have overnight continuo"}, {"to": "3373", "prefix": "t Interaction\n                  \n                  Because ", "from": "3367", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " reduces blood lymphocyte counts via redistribution in secon"}, {"to": "3583", "prefix": "ate the lymphocyte subset status of a patient treated with ", "from": "3577", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": ". A recent CBC should be available before initiating treatme"}, {"to": "3658", "prefix": "t CBC should be available before initiating treatment with ", "from": "3652", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": ".\n               \n               \n               \n          "}, {"to": "4036", "prefix": "ttenuated vaccines during, and for 2 months after stopping ", "from": "4030", "name": "fingolimod", "fullId": "http://purl.bioontology.org/ontology/MESH/C098720", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "GILENYA", "suffix": " treatment. "}, {"to": "595", "prefix": "e.g., ", "from": "586", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "citalopram", "suffix": ", chlorpromazine, haloperidol, methadone, erythromycin"}, {"to": "611", "prefix": "e.g., citalopram, ", "from": "598", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "chlorpromazine", "suffix": ", haloperidol, methadone, erythromycin"}, {"to": "624", "prefix": "e.g., citalopram, chlorpromazine, ", "from": "614", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "haloperidol", "suffix": ", methadone, erythromycin"}, {"to": "635", "prefix": "e.g., citalopram, chlorpromazine, haloperidol, ", "from": "627", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "methadone", "suffix": ", erythromycin"}, {"to": "649", "prefix": "e.g., citalopram, chlorpromazine, haloperidol, methadone, ", "from": "638", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "erythromycin", "suffix": ""}, {"to": "847", "prefix": "].\n                  \n                     ", "from": "836", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D007654", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Ketoconazole", "suffix": "\n                  \n                  The blood levels of fi"}, {"to": "1008", "prefix": "ate are increased by 1.7-fold when used concomitantly with ", "from": "997", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D007654", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "ketoconazole", "suffix": ". Patients who use GILENYA and systemic ketoconazole concomi"}, {"to": "1060", "prefix": "y with ketoconazole. Patients who use GILENYA and systemic ", "from": "1049", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D007654", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "ketoconazole", "suffix": " concomitantly should be closely monitored, as the risk of a"}, {"to": "3813", "prefix": "      \n                        \n                           ", "from": "3802", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D007654", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "Ketoconazole", "suffix": ": Closely monitor during concomitant use with systemic ketoc"}, {"to": "3880", "prefix": "zole: Closely monitor during concomitant use with systemic ", "from": "3869", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D007654", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "ketoconazole", "suffix": ". "}, {"to": "2059", "prefix": "witching from drugs with prolonged immune effects, such as ", "from": "2049", "name": "natalizumab", "fullId": "http://purl.bioontology.org/ontology/MESH/C469407", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "natalizumab", "suffix": ", teriflunomide or mitoxantrone, the duration and mode of ac"}, {"to": "2074", "prefix": " drugs with prolonged immune effects, such as natalizumab, ", "from": "2062", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "teriflunomide", "suffix": " or mitoxantrone, the duration and mode of action of these d"}, {"to": "2090", "prefix": "nged immune effects, such as natalizumab, teriflunomide or ", "from": "2079", "name": "Mitoxantrone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7005", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "mitoxantrone", "suffix": ", the duration and mode of action of these drugs must be con"}, {"to": "2406", "prefix": "e.g., beta blockers or ", "from": "2398", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "diltiazem", "suffix": ""}, {"to": "2672", "prefix": "in, or heart rate-slowing calcium channel blockers such as ", "from": "2664", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "diltiazem", "suffix": " or verapamil"}, {"to": "2606", "prefix": "e.g., beta blockers, ", "from": "2600", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "digoxin", "suffix": ", or heart rate-slowing calcium channel blockers such as dil"}, {"to": "2685", "prefix": "rate-slowing calcium channel blockers such as diltiazem or ", "from": "2677", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "cc9e1c8c-0e2b-44e2-878b-27057f786be9", "exact": "verapamil", "suffix": ""}, {"to": "273", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Teriflunomide", "suffix": ", an immunomodulatory agent with anti-inflammatory propertie"}, {"to": "482", "prefix": "de novo pyrimidine synthesis. The exact mechanism by which ", "from": "470", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " exerts its therapeutic effect in multiple sclerosis is unkn"}, {"to": "1250", "prefix": " performed in healthy subjects, there was no evidence that ", "from": "1238", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " caused QT interval prolongation of clinical significance "}, {"to": "1756", "prefix": "macokinetics\n                     \n                        ", "from": "1744", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Teriflunomide", "suffix": " is the principal active metabolite of leflunomide and is re"}, {"to": "1897", "prefix": " for leflunomide's activity in vivo. At recommended doses, ", "from": "1885", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " and leflunomide result in a similar range of plasma concent"}, {"to": "1981", "prefix": "mide result in a similar range of plasma concentrations of ", "from": "1969", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": ".\n                        Based on a population analysis of "}, {"to": "2054", "prefix": "\n                        Based on a population analysis of ", "from": "2042", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " in healthy volunteers and MS patients, median t1"}, {"to": "2810", "prefix": "en 1 to 4 hours post-dose following oral administration of ", "from": "2798", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": ".\n                              Food does not have a clinica"}, {"to": "2906", "prefix": "        Food does not have a clinically relevant effect on ", "from": "2894", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " pharmacokinetics.\n                           \n             "}, {"to": "3310", "prefix": "                            \n                              ", "from": "3298", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Teriflunomide", "suffix": " is extensively bound to plasma protein "}, {"to": "3860", "prefix": "                            \n                              ", "from": "3848", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Teriflunomide", "suffix": " is the major circulating moiety detected in plasma. The pri"}, {"to": "3988", "prefix": " primary biotransformation pathway to minor metabolites of ", "from": "3976", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " is hydrolysis, with oxidation being a minor pathway. Second"}, {"to": "4503", "prefix": "                            \n                              ", "from": "4491", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Teriflunomide", "suffix": " is eliminated mainly through direct biliary excretion of un"}, {"to": "4905", "prefix": "er a single IV administration, the total body clearance of ", "from": "4893", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " is 30.5 mL"}, {"to": "5317", "prefix": "                            \n                              ", "from": "5305", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Teriflunomide", "suffix": " is not metabolized by Cytochrome P450 or flavin monoamine o"}, {"to": "6004", "prefix": ", following repeated doses of ", "from": "5992", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " and a single dose of 0.25 mg repaglinide, suggesting that t"}, {"to": "6076", "prefix": " and a single dose of 0.25 mg repaglinide, suggesting that ", "from": "6064", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " is an inhibitor of CYP2C8 in vivo. The magnitude of interac"}, {"to": "6396", "prefix": "                                        \nRepeated doses of ", "from": "6384", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " decreased mean Cmax and AUC of caffeine by 18% and 55%, res"}, {"to": "6496", "prefix": " of caffeine by 18% and 55%, respectively, suggesting that ", "from": "6484", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " may be a weak inducer of CYP1A2 in vivo.\n                  "}, {"to": "6809", "prefix": ", following repeated doses of ", "from": "6797", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": ", suggesting that teriflunomide is an inhibitor of organic a"}, {"to": "6840", "prefix": "following repeated doses of teriflunomide, suggesting that ", "from": "6828", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " is an inhibitor of organic anion transporter 3 "}, {"to": "7223", "prefix": ", following repeated doses of ", "from": "7211", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " , suggesting that teriflunomide is an inhibitor of BCRP tra"}, {"to": "7255", "prefix": "ollowing repeated doses of teriflunomide , suggesting that ", "from": "7243", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " is an inhibitor of BCRP transporter and organic anion trans"}, {"to": "7748", "prefix": " following repeated doses of ", "from": "7736", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " [see Drug Interactions "}, {"to": "7830", "prefix": "].\n                                       ", "from": "7818", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Teriflunomide", "suffix": " did not affect the pharmacokinetics of   bupropion "}, {"to": "8628", "prefix": "nducers: Rifampin did not   affect the pharmacokinetics of ", "from": "8616", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": ".\n                                    \n                     "}, {"to": "9336", "prefix": "epatic impairment had no impact on the pharmacokinetics of ", "from": "9324", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": ". The pharmacokinetics of teriflunomide in severe hepatic im"}, {"to": "9375", "prefix": "pharmacokinetics of teriflunomide. The pharmacokinetics of ", "from": "9363", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " in severe hepatic impairment have not been evaluated [see C"}, {"to": "9733", "prefix": " renal impairment had no impact on the pharmacokinetics of ", "from": "9721", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " [see Use in Specific Populations "}, {"to": "9951", "prefix": "         \nIn a population analysis, the clearance rate for ", "from": "9939", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " is 23% less in females than in males.\n                     "}, {"to": "10157", "prefix": "                \nEffect of race on the pharmacokinetics of ", "from": "10145", "name": "teriflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C527525", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "teriflunomide", "suffix": " cannot be adequately assessed due to a low number of non-wh"}, {"to": "428", "prefix": " dehydrogenase, a mitochondrial enzyme involved in de novo ", "from": "419", "name": "pyrimidine", "fullId": "http://purl.bioontology.org/ontology/MESH/C030986", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "pyrimidine", "suffix": " synthesis. The exact mechanism by which teriflunomide exert"}, {"to": "1806", "prefix": "       Teriflunomide is the principal active metabolite of ", "from": "1796", "name": "leflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C045463", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "leflunomide", "suffix": " and is responsible for leflunomide's activity in vivo. At r"}, {"to": "1841", "prefix": "al active metabolite of leflunomide and is responsible for ", "from": "1831", "name": "leflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C045463", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "leflunomide", "suffix": "'s activity in vivo. At recommended doses, teriflunomide and"}, {"to": "1913", "prefix": " activity in vivo. At recommended doses, teriflunomide and ", "from": "1903", "name": "leflunomide", "fullId": "http://purl.bioontology.org/ontology/MESH/C045463", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "leflunomide", "suffix": " result in a similar range of plasma concentrations of terif"}, {"to": "4775", "prefix": ". After an accelerated elimination procedure with ", "from": "4762", "name": "Cholestyramine Resin", "fullId": "http://purl.bioontology.org/ontology/MESH/D002792", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "cholestyramine", "suffix": ", an additional 23.1% was recovered "}, {"to": "5677", "prefix": "                                   The Potential Effect of ", "from": "5671", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": " on Other Drugs\n                                    \n       "}, {"to": "8451", "prefix": "                    The Potential Effect of Other Drugs on ", "from": "8445", "name": "Aubagio", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1310526", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "AUBAGIO", "suffix": "\n                                    \n                      "}, {"to": "5914", "prefix": "                            \nThere was an increase in mean ", "from": "5904", "name": "repaglinide", "fullId": "http://purl.bioontology.org/ontology/MESH/C072379", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "repaglinide", "suffix": " Cmax and AUC "}, {"to": "6045", "prefix": "peated doses of teriflunomide and a single dose of 0.25 mg ", "from": "6035", "name": "repaglinide", "fullId": "http://purl.bioontology.org/ontology/MESH/C072379", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "repaglinide", "suffix": ", suggesting that teriflunomide is an inhibitor of CYP2C8 in"}, {"to": "6187", "prefix": "agnitude of interaction could be higher at the recommended ", "from": "6177", "name": "repaglinide", "fullId": "http://purl.bioontology.org/ontology/MESH/C072379", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "repaglinide", "suffix": " dose [see Drug Interactions "}, {"to": "6436", "prefix": "ated doses of teriflunomide decreased mean Cmax and AUC of ", "from": "6429", "name": "Caffeine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1886", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "caffeine", "suffix": " by 18% and 55%, respectively, suggesting that teriflunomide"}, {"to": "6717", "prefix": "                            \nThere was an increase in mean ", "from": "6710", "name": "Cefaclor", "fullId": "http://purl.bioontology.org/ontology/MESH/D002433", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "cefaclor", "suffix": " Cmax and AUC "}, {"to": "7131", "prefix": "                            \nThere was an increase in mean ", "from": "7120", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "rosuvastatin", "suffix": " Cmax and AUC "}, {"to": "7653", "prefix": " and ", "from": "7640", "name": "Levonorgestrel", "fullId": "http://purl.bioontology.org/ontology/MESH/D016912", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "levonorgestrel", "suffix": " Cmax and AUC0"}, {"to": "7881", "prefix": "    Teriflunomide did not affect the pharmacokinetics of   ", "from": "7873", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "bupropion", "suffix": " "}, {"to": "7913", "prefix": ", ", "from": "7905", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "midazolam", "suffix": " "}, {"to": "7946", "prefix": ", S-", "from": "7939", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "warfarin", "suffix": "   "}, {"to": "7981", "prefix": ", ", "from": "7972", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "omeprazole", "suffix": " "}, {"to": "8019", "prefix": ", and ", "from": "8010", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "metoprolol", "suffix": " "}, {"to": "8573", "prefix": "                      Potent CYP and transporter inducers: ", "from": "8566", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "4650d12c-b9c8-4525-b07f-a2d773eca155", "exact": "Rifampin", "suffix": " did not   affect the pharmacokinetics of teriflunomide.\n   "}]